These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21451421)

  • 1. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
    Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
    J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of eplerenone versus losartan in patients with low-renin hypertension.
    Weinberger MH; White WB; Ruilope LM; MacDonald TM; Davidson RC; Roniker B; Patrick JL; Krause SL
    Am Heart J; 2005 Sep; 150(3):426-33. PubMed ID: 16169319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    Williams GH; Burgess E; Kolloch RE; Ruilope LM; Niegowska J; Kipnes MS; Roniker B; Patrick JL; Krause SL
    Am J Cardiol; 2004 Apr; 93(8):990-6. PubMed ID: 15081441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
    Tomaschitz A; Verheyen N; Meinitzer A; Pieske B; Belyavskiy E; Brussee H; Haas J; März W; Pieske-Kraigher E; Verheyen S; Ofner-Ziegenfuss L; Hartaigh BÓ; Schwetz V; Aberer F; Grübler M; Lang F; Alesutan I; Voelkl J; Gaksch M; Horina JH; Dimai HP; Rus-Machan J; Stiegler C; Ritz E; Fahrleitner-Pammer A; Pilz S
    J Hypertens; 2016 Jul; 34(7):1347-56. PubMed ID: 27065001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.